Tumour-infiltrating lymphocyte therapy has shown durable responses in refractory melanoma, including a 31.4% objective response rate in phase II data. The 2024 FDA approval of Lifileucel marked a milestone as regulators in other markets continue reviews.
Diakonos Oncology's Phase 2 glioblastoma trial of DOC1021 continues after independent safety review found no concerns. The company will present clinical data on the dendritic cell therapy at AACR and AAN conferences in April 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07288112 |
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma |
RECRUITING | PHASE1/PHASE2 |
| NCT05039801 |
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT04284774 |
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03175432 |
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT02298959 |
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer |
ACTIVE_NOT_RECRUITING | PHASE1 |
